Fundz
Following Kanvas Biosciences?

Get the free weekly funding digest

The latest funding rounds, like Kanvas Biosciences’s — who’s behind them and what they mean, delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New funding rounds, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Industry Trends

See who's moving and how much in your market

No credit card required Weekly funding digest

Kanvas Biosciences secures $48M Series A funding led by DCVC and Lions Capital to advance immunotherapy treatments for cancer patients.

PRIVATEMay 06, 2026•about 2 months ago

Amount Raised

$48 Million

Round Type

series a

Monmouth JunctionBiotechnologyHealthcare

Investors

Pangaea VenturesKi Tua FundGermin8Athos KgGates FoundationLions Capital LlcDcvc

Description

Kanvas Biosciences has raised $48 million in a Series A funding round to advance its lead immuno-oncology drug, KAN-001, aimed at improving treatment efficacy for cancer patients. The round includes investors like DCVC, Lions Capital LLC, and Gates Foundation. This funding will support clinical trials and enhance commercial partnerships leveraging their spatial imaging and manufacturing platform. Kanvas has now raised a total of $78 million in funding.

Company Information

Company

Kanvas Biosciences

Location

1 DEER PARK DRIVE

Monmouth Junction, New Jersey, United States

About

Kanvas Biosciences is building the world's first microbiome drug screening and drug discovery platform to accelerate live biotherapeutic product (LBP) development. Leveraging its unparalleled ability to spatially map the microbiome and profile host-gene expression at single-cell resolution, the company is constructing the most comprehensive and robust microbiome data resource for future drug development. Kanvas Biosciences' technology was initially developed at Cornell University and exclusively licensed. The company's notable investors include DCVC, Lions Capital LLC, Cooke LLC, Uncommon Denominator, and Triple Impact Capital.

Related People

Suggested for you
1 contact

Choose your plan to reveal verified contacts

Predictive Intelligence
Strategic

ML-powered predictions for Kanvas Biosciences's next move

Learn about Strategic plan

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.

Watching Kanvas Biosciences? See every signal — funding, hires, M&A, contracts, sentiment.

Request a demoChoose your plan